Y0000709
Oxitropium bromide
European Pharmacopoeia (EP) Reference Standard
Sign Into View Organizational & Contract Pricing
Select a Size
About This Item
Empirical Formula (Hill Notation):
C19H26BrNO4
CAS Number:
Molecular Weight:
412.32
UNSPSC Code:
41116107
NACRES:
NA.24
grade
pharmaceutical primary standard
API family
oxitropium
manufacturer/tradename
EDQM
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
[Br-].[N+]1(C2C3OC3C1CC(C2)OC(=O)C(CO)c4ccccc4)(CC)C
InChI
1S/C19H26NO4.BrH/c1-3-20(2)15-9-13(10-16(20)18-17(15)24-18)23-19(22)14(11-21)12-7-5-4-6-8-12;/h4-8,13-18,21H,3,9-11H2,1-2H3;1H/q+1;/p-1
InChI key
LCELQERNWLBPSY-UHFFFAOYSA-M
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Oxitropium bromide EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.
Packaging
The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.
Other Notes
Sales restrictions may apply.
Regulatory Information
监管及禁止进口产品
This item has
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Cristoforo Incorvaia et al.
Respiratory medicine, 101(3), 476-480 (2006-08-22)
Inhaled bronchodilators are first line drugs in the treatment of chronic obstructive pulmonary disease (COPD). Tiotropium bromide is a recently introduced long-acting anticholinergic agent able to reduce dyspnoea and COPD exacerbations and to improve pulmonary function and quality of life.
Bruno Sposato et al.
The Journal of asthma : official journal of the Association for the Care of Asthma, 45(5), 397-401 (2008-06-24)
The protective effect of inhaled anticholinergic drugs in the methacholine-induced bronchospasm is well-known. The objective of this study was to assess if any possible differences may be found among Ipratropium (IB), Oxitropium (OXI) and Tiotropium (TIO) pre-treatments to obtain the
Kai-Michael Beeh et al.
Respiration; international review of thoracic diseases, 69(4), 372-379 (2002-08-10)
Chronic obstructive pulmonary disease (COPD) is one of the leading causes of morbidity and mortality in the world. In the majority of cases, the disease is the result of years of cigarette smoking. Contributing factors leading to bronchial obstruction in
Y Nakano et al.
The Journal of allergy and clinical immunology, 106(3), 472-478 (2000-09-13)
The efficacy of combination therapy adding multiple doses of anticholinergics to beta(2)-agonists to improve outcome has not been established in adults with acute severe asthma. This study was undertaken to compare the outcome of adults with acute severe asthma treated
Takanobu Shioya et al.
Arzneimittel-Forschung, 58(1), 24-28 (2008-03-29)
The present study was undertaken to evaluate the long-term effect of procaterol hydrochloride (CAS 62929-91-3, Meptin), a third generation beta2-receptor agonist on lung function, exercise capacity, health-related quality of life (HRQOL) and activities of daily living (ALDs) in patients with
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service